By Rick Archer (February 24, 2022, 7:07 PM EST) – Bankrupt generic pharmaceutical company Teligent Inc. has told a Delaware bankruptcy judge that there remains an impasse in talks over a restructuring plan and expiration its authorization to use cash collateral. no choice but to pivot into liquidation.
In a motion filed late Wednesday, Teligent asked the court to convert its Chapter 11 case to a Chapter 7 liquidation, saying it had been unable to reach an agreement with its creditors on a reorganization plan. and that “growing expenses” were eating away at its remainder. assets.
“As a result, and without the consensual use of cash collateral to fund a…
Stay one step ahead
In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.
Access to case data in articles (numbers, filings, courts, nature of lawsuits, etc.)
Access to attached documents such as briefs, motions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and more!